{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vascular:pharmacology:antiplatelet:clopidogrel",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-07T00:55:00.000Z",
    "updated": "2026-01-07T00:55:00.000Z",
    "contributors": [
      "vascular-surgery-agent"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "identifier": "PHARM-011",
    "title": "Clopidogrel (P2Y12 Inhibitor)",
    "definition": "Thienopyridine prodrug antiplatelet agent that irreversibly inhibits P2Y12 ADP receptor on platelets.",
    "concepts": [
      {
        "concept_id": "mechanism",
        "term": "Mechanism of Action",
        "definition": "Prodrug requiring hepatic CYP2C19 activation to active metabolite that irreversibly binds P2Y12 receptor.",
        "clinical_features": {
          "receptor": "P2Y12 ADP receptor",
          "binding": "Irreversible (platelet lifespan effect)",
          "cyp_activation": "CYP2C19 primary, also CYP3A4, CYP1A2",
          "onset": "2-4 hours with loading dose"
        }
      },
      {
        "concept_id": "dosing",
        "term": "Clopidogrel Dosing",
        "definition": "Loading and maintenance dosing for various vascular indications.",
        "clinical_features": {
          "loading": "300-600 mg",
          "maintenance": "75 mg daily",
          "acs": "600 mg load, 75 mg daily for 12 months",
          "stroke": "75 mg daily (no loading per CHANCE)"
        }
      },
      {
        "concept_id": "resistance",
        "term": "Clopidogrel Resistance",
        "definition": "Variable antiplatelet response due to genetic and drug factors.",
        "clinical_features": {
          "cyp2c19_polymorphism": {
            "poor_metabolizers": "2-15% of population",
            "lof_alleles": "*2, *3 most common",
            "clinical_impact": "Increased stent thrombosis risk"
          },
          "drug_interactions": [
            "PPI (omeprazole strongest)",
            "CYP2C19 inhibitors"
          ],
          "alternatives": [
            "Prasugrel",
            "Ticagrelor"
          ]
        }
      },
      {
        "concept_id": "indications",
        "term": "Vascular Surgery Indications",
        "definition": "Role of clopidogrel in vascular surgery patients.",
        "clinical_features": {
          "carotid_stent": "DAPT for minimum 30 days, ideally 3-6 months",
          "peripheral_stent": "DAPT for 1-3 months",
          "aspirin_intolerance": "Alternative monotherapy",
          "pad": "May be superior to aspirin (CAPRIE)"
        }
      }
    ],
    "clinical_features": {
      "perioperative": "Hold 5-7 days pre-elective surgery",
      "testing": "CYP2C19 genotyping or platelet function testing in high-risk"
    },
    "diagnostic_criteria": {
      "platelet_inhibition": "PRU <208 considered adequate on VerifyNow"
    },
    "statement": "Clopidogrel (P2Y12 Inhibitor) is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Clopidogrel (P2Y12 Inhibitor) helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Clopidogrel (P2Y12 Inhibitor) include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Clopidogrel (P2Y12 Inhibitor)."
    }
  },
  "relationships": [
    {
      "type": "combined_with",
      "target": "vascular:pharmacology:aspirin"
    },
    {
      "type": "alternative_to",
      "target": "vascular:pharmacology:ticagrelor"
    },
    {
      "type": "used_in",
      "target": "vascular:procedures:stenting"
    }
  ],
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Clopidogrel (P2Y12 Inhibitor). Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}